Advertisements

Диаскинтест

Quick links to important sections

Диаскинтест

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Диаскинтест

Quick Facts

Property Description
Active ingredient Bacterial Allergens [tubercular Recombinant]
Form Sterile Solution (injectable)
Pharmacological class Diagnostic Agent (Immunological Diagnostic)
Common use Diagnosis of Tuberculosis and LTBI detection
Origin Biotechnologically Recombinant (synthetic proteins)

Defining Диаскинтест: Class and Identity

Диаскинтест is a modern, highly specific Diagnostic Agent classified as an Immunological Diagnostic preparation, functioning solely as a Tuberculosis Skin Test. It is not a therapeutic drug or a preventative vaccine. The preparation is a sterile Solution manufactured by Generium and is administered intradermally (into the skin) for diagnostic screening. This product has been recognized for its utility in simplifying the initial differentiation steps for individuals requiring TB evaluation.


Composition and Origin: The Recombinant Solution

The active ingredient(s) are formally described as Bacterial Allergens [tubercular Recombinant], consisting of two purified recombinant proteins: ESAT-6 and CFP-10. These proteins are produced synthetically using biotechnological methods. The specific recombinant origin is essential because the ESAT-6 and CFP-10 antigens are characteristic of virulent Mycobacterium tuberculosis but are absent in the BCG vaccine strain. Unlike older screening methods, Диаскинтест is positioned for use in all age groups, including children, where accurate screening is particularly critical.


General Purpose: Why is Диаскинтест Used?

The overarching general purpose of Диаскинтест is to aid in the definitive diagnosis of Tuberculosis infection, including the detection of Latent Tuberculosis Infection (LTBI). A typical scenario involves screening individuals who have had close contact with a known TB patient. The primary benefit of its targeted recombinant composition is its high specificity, which allows medical professionals to accurately differentiate between a true infection and the immune response resulting from BCG vaccination. This targeted assessment helps focus evaluation on individuals who require further management for the disease.

Regulatory References

  1. Tuberculosis (TB) - MedlinePlus
Advertisements

What side effects are possible with Диаскинтест?

Possible Side Effects and Safety Information

The safety profile of Диаскинтест, an immunological diagnostic agent, is characterized by local reactions at the administration site and a limited range of systemic effects, as documented in official regulatory sources.

Official Adverse Reactions and Safety Profile

Category Documented Characteristics
Local Reactions Pain, discomfort, itching, redness (erythema), and swelling (induration) at the injection site are common. Severe local reactions, including vesiculation, ulceration, or necrosis, are officially documented as possible, although rare, adverse outcomes.
Systemic Reactions Constitutional symptoms such as fever (pyrexia), headache, weakness, and chills are officially listed as possible systemic adverse reactions.
Serious Reactions The regulatory profile notes the possibility of anaphylaxis (severe allergic reaction) and syncope (fainting), sometimes associated with seizure-like activity, following the intradermal administration.

Time-Related Safety Patterns

The key diagnostic reaction—local induration—is typically expected to reach its maximum size 48 to 72 hours after administration, gradually subsiding thereafter. Other local effects, such as non-indurated redness or hemorrhage, may appear earlier, within the first three days following the test.

Safety Restrictions and Considerations

Official labeling defines specific restrictions on use. The diagnostic agent is contraindicated in individuals with a known hypersensitivity or allergy to any component of the solution. Use is also restricted for persons with a history of a severe local reaction (e.g., necrosis or blistering) to a similar previous skin test. Regulatory documentation also notes that recent live virus vaccination or the use of immunosuppressive agents may depress the immune response, which can affect the test's outcome, but this is a diagnostic consideration rather than a direct safety consequence.

Advertisements

Overdose and Emergency Response

The official regulatory documentation addresses potential overdose scenarios for Диаскинтест (Bacterial Allergens [tubercular Recombinant]) primarily through mandated emergency actions rather than specific symptom profiles. Due to the product’s function as an intradermal diagnostic solution administered in a minimal, standard volume, official labeling confirms that no specific clinical profile of toxicological signs or symptoms is officially documented in the prescribing information. Overdose is often characterized by the administration of an abnormally high volume of the solution or an incorrect injection route, which could lead to unforeseen severe systemic reactions.

The regulator-mandated guidance is to seek immediate medical attention for any severe, unexpected systemic reaction that occurs following administration. Individuals must contact emergency services immediately if any life-threatening clinical signs are observed, as hospital monitoring may be required to manage potential severe effects. Management procedures are strictly limited to symptomatic and supportive treatment to address the patient's clinical signs. The official prescribing information confirms that no specific antidote is known or listed for the recombinant protein components. This mandated action-focused approach guides the required response to any event of suspected over-administration.

Advertisements

Therapeutic Uses of Диаскинтест

What Диаскинтест Treats: Main Uses and Benefits

The utility of Диаскинтест is generally applied within the area of immunological diagnostics for Tuberculosis (TB), providing key information that helps inform patient management and risk assessment. Its primary benefit is providing clarity in situations of diagnostic uncertainty. The test is relevant for addressing the challenge of identifying the presence of Mycobacterium tuberculosis in the body, which is a necessary step before any preventative or therapeutic plan can be established.

Диаскинтест is commonly used to manage diagnostic ambiguity in three main contexts: to help resolve suspicion of Latent Tuberculosis Infection (LTBI), to assist in evaluating individuals with possible Active Tuberculosis, and to clarify indistinct immunological responses in individuals previously given the BCG vaccine. This differentiation capability supports management of the diagnostic uncertainty regarding a true infection. This diagnostic support assists in managing the condition, contributing to functional stability in clinical settings that involve heightened systemic burden.

“This diagnostic capability supports patients by easing distress and contributes to improved comfort during periods of potential concern.”

Quick Fact: Clarity in Diagnostic Uncertainty
Primary Use Detection of M. tuberculosis infection (LTBI and Active TB)
Key Benefit Assisting in the differentiation of infection from BCG vaccination response
Scenarios Preventive screening, contact tracing, and risk stratification in high-risk groups

Regulatory References

  1. National Center for Biotechnology Information (NCBI) on TB skin tests
Advertisements

Eligibility and Restrictions for Use

The official regulatory profile for Диаскинтест defines clear populations for eligibility, restriction, and exclusion. Eligibility is established for all age groups (children, adolescents, and adults), as age-related restrictions are formally absent. Furthermore, no special use features are noted for patients with impaired liver or kidney function.


Contraindications and Restrictions

Classification Population/Condition
Absolute Contraindication Acute infectious diseases, chronic diseases in the stage of exacerbation, epilepsy, widespread skin diseases, or hypersensitivity to the components.
Conditional Use Pregnancy and lactation (use permitted only if the estimated benefit outweighs the potential unknown risk, as safety data is not studied).
Temporal Restriction Must be postponed if the individual is within one month of a prophylactic vaccination or is under quarantine for childhood infections.

These limitations are designed to prevent interference with the immunological diagnostic test or to avoid administration during periods of heightened systemic illness.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Диаскинтест (Bacterial Allergens [tubercular Recombinant]), an immunological diagnostic agent, is governed by restrictions related to the timing of administration with other immune-modulating products, rather than systemic pharmacokinetic effects.


Pharmacokinetic and Systemic Non-Interactions

Official regulatory documentation confirms that the product is administered intradermally in a minimal dose and practically does not penetrate the systemic circulation. This lack of systemic exposure results in no documented interactions involving metabolic enzymes (such as CYP450) or drug transporters. Consequently, the label states that no dose adjustment or special interaction caution is required for patients with impaired hepatic or renal function.


Immunological Interference and Timing Requirements

The clinically significant interaction involves pharmacodynamic interference with the required immune response. The test must be scheduled and performed before any Prophylactic Vaccination.

If prophylactic vaccinations have already been administered, the test procedure must be carried out no earlier than 1 month after the date of the vaccination to prevent an inaccurate diagnostic result. Furthermore, for individuals with a history of non-specific allergy, regulatory instructions recommend conducting the test while taking desensitizing preparations for a specified period (5 days before and 2 days after the test).

Advertisements

Mechanism of Action

How Диаскинтест Works: Mechanism of Action

The mechanism involves the Delayed-Type Hypersensitivity (DTH) immune response.

Targeting Specific T-Cell Memory

The test works by targeting antigen-specific effector and memory T-lymphocytes via two highly selective recombinant antigens: ESAT-6 and CFP-10. The intradermal injection introduces these proteins locally, where Antigen-Presenting Cells capture them. The binding of the presented antigens to T-cell receptors activates T-cells previously sensitized by Mycobacterium tuberculosis infection, initiating the core cellular immune process.

Initiating the DTH Inflammatory Cascade

Activation of these specific T-cells triggers a mechanistic cascade involving the rapid release of pro-inflammatory cytokines, such as Interferon-gamma (IFN-gamma), and chemokines. These mediators recruit other immune cells, specifically monocytes and macrophages, to the injection site, leading to a localized cellular infiltration.

Physiological Outcome: Induration

The result of the cellular infiltration and increased vascular permeability is induration (localized skin thickening and hardening) and erythema. This physiological effect is the visible manifestation of the underlying T-cell mediated response, providing a measurable consequence of the immune recognition of the targeted M. tuberculosis antigens.

Advertisements

Dosage and Administration Information

How to Use Диаскинтест

Диаскинтест is utilized as a diagnostic agent under a standardized protocol to assess for tuberculosis infection. Its administration follows official regulatory instructions, which define the procedure, dose, and required timing for result assessment. The test is administered by a healthcare professional as a single, event-based procedure, meaning it is not part of a daily or long-term medication regimen.


Official Administration Guidelines

The entire process is defined by strict regulatory parameters to ensure the accuracy of the immunological response. The required route of administration is intradermal injection only. The test must not be administered by any other route, such as subcutaneous or intravenous.

Administration Scope Regulatory Instruction
Route of Administration Intradermal injection.
Dosing Schedule A single, fixed dose of 0.2 mug of the recombinant protein complex in 0.1 mL of solution.
Age-Group Rule The same fixed dose is applied universally to all individuals, including children and adolescents.

Procedural Structure and Timing

Administration involves drawing the sterile solution into a tuberculin syringe and injecting the precise 0.1 mL volume into the inner surface of the forearm. The injection site must remain undisturbed and unbandaged until the assessment is complete. A critical component of the official use protocol is the mandatory time-bound assessment: the resulting skin reaction must be officially measured and evaluated 72 hours (3 days) after administration. This standardized procedure defines the entire administration pattern based on national regulatory standards.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Диаскинтест

Studies for the Detection of Latent TB Infection (LTBI)

The research base includes systematic reviews, meta-analyses, and observational studies. These studies were primarily conducted to evaluate diagnostic performance in individuals who may have been exposed to tuberculosis (contacts) and assessed for Latent Tuberculosis Infection (LTBI).

Studies primarily explored Diagnostic Specificity, which is the ability to correctly identify people who are truly uninfected, and evaluated concordance with other diagnostic tests, such as the blood-based Interferon-Gamma Release Assays (IGRA). Research describes patterns of concordance when results were compared against other diagnostic tests, though evidence quality varied across primary studies. There is limited information for long-term outcomes, specifically regarding the test's capability to predict whether an individual with a positive LTBI result will later develop active disease.


Research on Distinguishing Infection from BCG Vaccination

A key area of research explored by multiple comparative studies is the test's use in cohorts previously exposed to the BCG vaccination. Research examined outcomes related to diagnostic specificity in these vaccinated groups. Multiple studies report patterns related to a low rate of observed reaction in BCG-vaccinated individuals without documented infection. Research explored the patterns of reactivity that were intended to distinguish from BCG vaccination response.


Evidence in Support of Active Tuberculosis Diagnosis

The research base for Active Tuberculosis evaluated the test’s performance in cohorts of individuals with confirmed disease, utilizing comparative diagnostic accuracy studies and retrospective analyses. Research examined outcomes related to Diagnostic Sensitivity, which is the ability to correctly identify the presence of disease. Data show patterns related to the observed test results in patients with confirmed active disease. Evidence certainty remains low in some areas of this research, primarily due to methodological limitations such as reliance on unblinded data.


What Remains Uncertain in the Research Landscape

The evidence base has several limitations that create ongoing uncertainty. Evidence quality varies across studies, often noting a high risk of bias in the underlying primary studies. A key gap in the research landscape is the lack of comprehensive long-term evidence. While research describes short-term changes, there is limited information for long-term outcomes related to durability and infection progression over many years.

Key Studies & References

  1. Tuberculin Skin Test
  2. Tuberculosis Skin Test (Tuberculin Skin Testing/TST)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Диаскинтест (FAQ)


Q: Can the Diaskintest injection site get wet?

Official regulatory guidance advises that the injection site must remain undisturbed and unbandaged until the results are assessed, which occurs 72 hours after administration. While specific instructions on showering or water contact are often omitted, the guidance emphasizes protecting the area from any friction, rubbing, or excessive moisture that could interfere with the accurate reading of the immune response.


Q: What happens if I wash my hand or the test site after Diaskintest?

The official instruction is to keep the test site undisturbed and free of rubbing. While washing the hand is generally considered acceptable, regulatory guidance emphasizes that contact with the injection site on the forearm should be avoided to prevent friction or disturbance until the official measurement at 72 hours.


Q: Can I exercise after the test?

Regulatory instructions require the injection site to remain undisturbed until the final assessment. Activities that may cause significant friction, rubbing, or trauma to the injection site, such as heavy exercise or strenuous sports, are often discouraged to ensure the integrity of the test site is maintained until the result is read.


Q: How does Diaskintest differ from the Mantoux test?

Diaskintest is an immunological diagnostic agent that uses two specific recombinant proteins (ESAT-6 and CFP-10) to target a highly specific immune response. In contrast, the Mantoux (Tuberculin Skin Test) uses Purified Protein Derivative (PPD), which is less specific and can sometimes show a reaction due to prior BCG vaccination.


Q: Why is Diaskintest considered more specific/accurate?

The recombinant proteins used in Diaskintest (ESAT-6 and CFP-10) are specifically characteristic of virulent Mycobacterium tuberculosis but are absent in the BCG vaccine strain. This composition is intended to provide high diagnostic specificity, which aids in differentiation between a true infection and the immune response resulting from a prior BCG vaccination.


Q: Can Diaskintest give a false-positive result?

As with many diagnostic tests, there is a potential for inaccurate interpretation or an unexpected result. The specific antigens in Diaskintest are designed to reduce the false-positive rate compared to Mantoux in BCG-vaccinated individuals, but incorrect measurement or interpretation remains a potential cause of error.


Q: What reaction to Diaskintest is considered normal (negative)?

The 'normal' or negative reaction is the absence of a significant immunological response. Official guidelines define a negative result based on the size (in millimeters) of the resulting induration, which should fall below a defined threshold, as determined by a healthcare professional.


Q: What does a 'positive reaction' mean?

A positive reaction means the body’s immune system has recognized the recombinant proteins, resulting in a measurable induration (localized skin thickening and hardening) that exceeds the defined threshold. This result suggests the presence of a Mycobacterium tuberculosis infection.


Q: When is the best time to do Diaskintest?

The test must be performed when the individual is generally healthy and not experiencing an acute infectious disease or a flare-up of a chronic disease, as these can interfere with the results. It is also subject to specific timing requirements, such as waiting at least one month after any prophylactic vaccination.


Q: How often can Diaskintest be done?

The test is administered only when there is a clinical indication for screening or follow-up evaluation. There are no official recommendations for routine annual testing unless the individual belongs to a high-risk group or has had a recent exposure that requires re-assessment.


Q: What should I do if the injection site is itchy?

Itching (pruritus) at the injection site is listed in regulatory documentation as a common local adverse reaction. The site must remain undisturbed and should not be scratched or rubbed. Any persistent or unusually severe irritation should be reported to the healthcare professional performing the final assessment.


Q: Can Diaskintest cause a fever?

Yes, regulatory documents list systemic symptoms such as fever (pyrexia), weakness, and chills as possible adverse reactions following administration of the diagnostic agent.


Q: Can I eat certain foods before the test?

Official regulatory documentation for this diagnostic agent does not list any specific restrictions or requirements regarding food or fasting before the test procedure. Preparation is generally limited to timing relative to illness and other immunological interventions.


Q: Can Diaskintest be done during a cold?

No, the test is absolutely contraindicated (officially restricted) during acute infectious diseases, which includes the common cold (proстуда). The presence of a systemic infection can potentially interfere with the required immunological response and test validity.


Q: Does allergy affect the result of Diaskintest?

Yes, non-specific allergy can potentially interfere with the diagnostic result. Official instructions describe the use of desensitizing preparations, such as antihistamines, for a specified period around the test date for individuals with a known history of non-specific allergy, to manage potential interference.


Q: Can the test be done if a child has asthma?

The test is contraindicated if the individual has chronic diseases (such as asthma) that are currently in the stage of exacerbation (a flare-up). The test may be performed during stable, non-exacerbated periods of a chronic disease.


Q: How long after BCG vaccination can Diaskintest be done?

The official temporal restriction states that the test must be postponed if the individual is within one month of any prophylactic vaccination, including the BCG vaccine. This waiting period is necessary to ensure the vaccination does not interfere with the immunological response needed for an accurate test result.


Q: Do hormonal drugs affect the result?

The regulatory profile specifically cautions that the use of immunosuppressive agents can depress the immune response, which may affect the test outcome. This category of drugs includes high-dose or long-term systemic corticosteroids, which are hormonal preparations. Other hormonal drugs, such as birth control, are generally not listed as contraindications.


Q: How is the result checked—is it redness or only the papule/induration?

The official interpretation relies on measuring the diameter of the induration (the localized skin thickening and hardening), not the erythema (redness). The induration is the visible manifestation of the underlying cellular T-cell mediated response, which is the key diagnostic sign.


Q: What is a 'doubtful' result?

The result is officially classified as 'doubtful' when the induration measurement falls within a specific range defined in the regulatory guidelines. This result is neither clearly negative nor clearly positive, and it indicates the need for further clinical evaluation or follow-up testing.


Q: How long after administration does the result become invalid?

The skin reaction must be officially measured and evaluated exactly 72 hours after administration. If the reading is performed significantly later than the required time window, the diagnostic reaction may have subsided, potentially rendering the result uninterpretable and invalid.


Q: Why isn't Diaskintest given to everyone?

The test is not performed on everyone due to official regulatory Absolute Contraindications. These restrictions include, but are not limited to, acute infectious diseases, chronic diseases in the stage of exacerbation, epilepsy, widespread skin diseases, and known hypersensitivity to the components of the solution.


Q: Is it true that it is primarily done only in Russia?

Diaskintest is specifically manufactured in Russia and is primarily used under Russian regulatory guidelines. However, the core methodology, which uses ESAT-6 and CFP-10 recombinant antigens, is the foundation for internationally recognized diagnostic blood tests (Interferon-Gamma Release Assays or IGRA).


Q: Can I take antihistamines before the test?

Official regulatory instructions describe that for individuals with a history of non-specific allergy, the test is sometimes conducted while taking desensitizing preparations (antihistamines) for a specified period (typically 5 days before and 2 days after the test) to manage potential allergic interference.


Q: Can Diaskintest be done if there was recent contact with a sick person?

Yes, the test is specifically indicated for screening individuals who have had close contact with a known TB patient. This is a common and appropriate use case to aid in the detection of Latent Tuberculosis Infection (LTBI).


Q: What is the maximum period between administration and checking?

The reaction must be measured and evaluated between 48 and 72 hours, with 72 hours being the mandatory checkpoint. If a patient returns significantly later, the reaction may have subsided, and the test may need to be repeated because the result would be considered invalid.


Q: What should be done if the test is positive?

A positive result indicates a probable immune response to M. tuberculosis infection. This result is considered an indicator for further medical evaluation, which typically includes diagnostic steps such as a chest X-ray and clinical assessment to determine the status of the infection.


Q: Can there be a bruise at the injection site?

The regulatory profile lists hemorrhage (bleeding) as a possible adverse reaction. While a bruise (hematoma) is not explicitly listed, it may occur as a minor, expected consequence of any intradermal injection and should generally subside on its own.


Q: Is special preparation needed before the procedure?

Special preparation is required regarding the timing of the test relative to recent prophylactic vaccinations and for individuals with a history of allergy, as these can interfere with the results. Outside of these timing-related restrictions, no specific preparation (such as fasting or dietary changes) is noted.


Q: Can Diaskintest be done with chronic diseases?

Yes, the test can generally be performed if the chronic disease is not in the stage of exacerbation (a flare-up). The test is only absolutely contraindicated when the chronic disease is acute or worsening, as this could interfere with the body's immune response.


Q: Is a negative reaction related to immunity?

Yes, a negative reaction is directly related to the immune system. It indicates the absence of a T-cell mediated Delayed-Type Hypersensitivity response, meaning the immune cells (T-lymphocytes) were not previously sensitized to the specific recombinant proteins used in the diagnostic solution.

Advertisements

How should Диаскинтест be stored and disposed of?

How to Store and Dispose of Диаскинтест (Diaskintest)

The storage and disposal of Диаскинтест (Diaskintest) must strictly follow official regulatory requirements to maintain the integrity of this immunological diagnostic solution.


Storage Requirements

Condition Requirement
Temperature Store refrigerated between 2°C and 8°C (36°F to 46°F).
Prohibited Do not freeze. The product must be discarded if freezing occurs.
Protection Must be protected from light and kept in the original container.

Stability and Disposal

Once the multi-dose vial is opened (first punctured), any unused solution must be discarded after 30 days. The product must be kept out of the reach of children. Disposal of expired or unused solution must be performed in accordance with local and national regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Диаскинтест found in:

A-Z Index: